Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
R&D channel feed
Battling low expectations and goliath rivals, Regeneron/Sanofi add positive Libtayo data in pursuit of blockbuster status
6 years ago
FDA+
Alnylam, Sarepta jump into Covid-19 game, as pandemic rekindles antiviral hopes of RNA-targeting technology
6 years ago
Coronavirus
In Focus
BioMarin broadens its gene therapy horizons with a new R&D alliance in rare cardio cases
6 years ago
Deals
Cell/Gene Tx
Newron's Merck KGaA-in licensed compound fails Rett Syndrome study, shares wilt
6 years ago
FDA cheers on Gilead's remdesivir with a snap emergency OK, giving biopharma a shot at redemption
6 years ago
FDA+
Coronavirus
Tick saliva-derived drug shows promise in mid-stage rare skin disease study
6 years ago
Bristol Myers Squibb gets priority review for AML drug as list of potential Celgene hits lengthens
6 years ago
FDA+
Commercial strategy for Gilead's Covid-19 drug-to-be remdesivir remains opaque, as chief O'Day emphasizes responsibility
6 years ago
Pharma
FDA+
10X: Moderna creates a billion-dose vaccine pact in a frenzied race to beat Covid-19 — globally
6 years ago
Coronavirus
After NIH trial, EMA begins rolling review for remdesivir, setting up potential authorizations in US and Europe
6 years ago
FDA+
Coronavirus
Congressional watchdog advises HHS to implement 'post-marketing' incentives to address dwindling antibiotic development efforts
6 years ago
Data on Gilead's antiviral bring hope for first Covid-19 drug approval
6 years ago
Coronavirus
Novartis spinout resTORbio reverse merges with T cell biotech after big PhIII failure
6 years ago
Cell/Gene Tx
Gilead — Pivotal Covid-19 study of remdesivir ‘met its primary endpoint,' is emergency authorization next?
6 years ago
Coronavirus
Full steam ahead, Pfizer goes bargain hunting in an age of coronavirus — with a special focus on cancer and rare diseases
6 years ago
Bioregnum
Coronavirus
Third Rock-backed startup's blood test can sniff out cancer in patients with no history of disease
6 years ago
Financing
Startups
Blueprint stumbles in PhIII GIST trial, sending stock sliding, but analysts preach caution
6 years ago
Gilead fires back in ongoing battle with HHS, suing the government for ‘secretly’ obtaining patents
6 years ago
Weeks after FDA delay, Roche, PTC unveil another batch of positive risdiplam data in severe SMA patients
6 years ago
FDA+
#AACR20 roundup: Tecentriq/Xtandi combo fails to show OS benefit, halting Roche's PD-L1 push into prostate cancer
6 years ago
An oncology upstart with some deep-pocket VC connections has a unicorn-sized venture round to back the pipeline
6 years ago
Financing
Startups
#AACR20: Early data suggest Novartis' Incyte-discovered MET inhibitor helps lung cancer patients with brain lesions
6 years ago
Axsome shares rocket up on a surprise win for late-stage Alzheimer’s agitation study — but this is no easy layup
6 years ago
Covid-19 roundup: Sanofi & Regeneron deliver disappointing news on IL-6; Alex Azar rumors are swirling at HHS
6 years ago
Coronavirus
First page
Previous page
203
204
205
206
207
208
209
Next page
Last page